Ophthalmology
Page 1 • 5 itemsGain critical insights into global ophthalmology drug development, market trends, and regulatory landscapes. Inform your pharma investment and BD strategy.
Alkeus Pharmaceuticals Presents Gildeuretinol Data for Stargardt Disease at ARVO 2026
Alkeus Pharmaceuticals announces clinical data presentation for investigational oral gildeuretinol treating Stargardt disease at ARVO 2026 meeting.
EMA Issues Positive Opinion for Rexatilux (Ranibizumab) Eye Treatment
European Medicines Agency issues positive opinion for Rexatilux ranibizumab, advancing potential new eye treatment option for European patients.
Belite Bio Submits New Drug Application for Tinlarebant to Treat Stargardt Disease Following Positive Phase 3 Results
Belite Bio initiates rolling NDA submission for tinlarebant after Phase 3 DRAGON trial showed 35.7% reduction in retinal lesion growth for Stargardt disease patients.
MeiraGTx Acquires Botaretigene Sparoparvovec Gene Therapy from Johnson & Johnson for X-linked Retinitis Pigmentosa Treatment
MeiraGTx acquired botaretigene sparoparvovec from J&J to treat X-linked retinitis pigmentosa, planning immediate global regulatory filings for approval.
Vabysmo Market Report 2026: Roche's Eye Drug Shows Strong Growth Through 2035 Amid Rising Retinal Disorder Cases
New market research reveals Vabysmo's projected growth through 2035, driven by advances in retinal disorder diagnosis and expanding ophthalmology clinics.